SCHEMBL5657399

SCHEMBL5657399

Cc1cc(C=O)cc2c3ccccc3n(C)c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH5 Q6P6C2 1/20 0.56
FTO Q9C0B1 1/20 0.56
KDM4E B2RXH2 4/20 0.50
NQO2 P16083 1/20 0.50
AHR P35869 1/20 0.49
MAPT P10636 4/20 0.46
GPR3 P46089 1/20 0.46
PTGER4 P35408 2/20 0.45
HSP90AA1 P07900 1/20 0.42
IDO1 P14902 1/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
NPSR1 Q6W5P4 3/20 0.40
HTT P42858 3/20 0.40
HPGD P15428 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15201411 0.84 ALKBH5 (0.49) ALKBH5FTOKDM4ENQO2AHR
SCHEMBL29045213 0.79 AHR (0.44) ALKBH5FTOKDM4ENQO2AHR
SCHEMBL21030544 0.78 ALKBH5 (0.65) ALKBH5FTOKDM4ENQO2AHR
SCHEMBL29570020 0.77 PTGER4 (0.64) KDM4ENQO2MAPTGPR3PTGER4
SCHEMBL718797 0.77 PTGER4 (0.64) KDM4ENQO2MAPTGPR3PTGER4
SCHEMBL18069040 0.76 ALKBH5 (0.67) ALKBH5FTOKDM4ENQO2AHR
SCHEMBL16414205 0.76 ALKBH5 (0.61) ALKBH5FTOKDM4ENQO2AHR
SCHEMBL17020173 0.76 PTGER4 (0.42) ALKBH5FTOKDM4ENQO2MAPT
SCHEMBL9779016 0.74 AHR (0.51) ALKBH5FTOKDM4ENQO2AHR
SCHEMBL25494880 0.74 ALKBH5 (0.59) ALKBH5FTOKDM4ENQO2AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MARZABADI MOHAMMAD R 2007-02-22 US disclosed
US-7067534-B1 Substituted anilinic piperidines as MCH selective antagonists H. LUNDBECK A/S (DK) 2006-06-27 US disclosed
CN-1671386-A Substituted anilinic piperidines as MCH selective antagonists LUNDBECK & CO AS H (DK) 2005-09-21 CN disclosed
EP-1411942-A4 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMA CORP (US) 2005-01-26 EP disclosed
EP-1411942-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS Synaptic Pharmaceutical Corporation (US) 2004-04-28 EP disclosed
US-6727264-B1 MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS SYNAPTIC PHARMACEUTICAL CORPORATION 2004-04-27 US disclosed
WO-2003004027-A1 SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043080-A1 Substituted anilinic piperidines as MCH selective antagonists MCHR1, MCHR2, MC1R ALKBH5 451/4885FTO 866/4885KDM4E 1353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.